| Therapeutic | Vonlerolizumab |
| Target | TNFRSF4 |
| Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK |
| 100% seqID Fv Structure | 6ogx [Fvs: CD], 6okn [Fvs: AB, CB] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6okn [Fvs: AB, CB] |
| 100% seqID Structure | 6ogx [Fvs: CD] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Discontinued |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2015 |
| INN Year Recommended | 2017 |
| Companies Involved | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours, Urogenital cancer |
| Notes | Vonlerolizumab and Pogalizumab are the same mAb |
